CRSP News and Press, CRISPR Therapeutics AG From 01/09/24

2024-01-09 13:40:50 ET More on CRISPR Therapeutics, Vertex Pharmaceuticals, etc. Vertex Pharmaceuticals Incorporated (VRTX) J.P. Morgan 42nd Annual Healthcare Conference Vertex Pharmaceuticals: A Full Pipeline CRISPR Therapeutics: Therapies Of The Future Are Almost H...

2024-01-08 15:36:52 ET More on CRISPR Therapeutics CRISPR Therapeutics: Therapies Of The Future Are Almost Here, But Not Yet Crispr Therapeutics Is Overvalued (Rating Downgrade) Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed ...

ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its n...

2024-01-08 05:00:00 ET A great way to boost your portfolio's growth is to get in on companies during the early stages of their growth stories. And one that fits the bill right now is CRISPR Therapeutics (NASDAQ: CRSP) . The biotech company recently won approval for its first product...

2024-01-05 06:40:30 ET Summary Agios Pharmaceuticals completed its IPO in 2013 and sold its oncology portfolio for $1.8bn in 2021. Its stock price is down 50% across a 5-year period. The company's focus is now on mitapivat, which has been approved for hemolytic anemia and is being...

2024-01-04 05:00:00 ET CRISPR Therapeutics (NASDAQ: CRSP) already had a huge 2023. The biotech scored its first product approval for the blood-disorders therapy Casgevy -- winning the world's first-ever regulatory nod for a product based on CRISPR gene-editing technology. The compan...

2024-01-04 02:10:41 ET Summary CRISPR Therapeutics is a gene therapy and gene editing company focused on developing gene-based medicines using CRISPR and Cas9 technologies. The company recently gained approval for Casgevy, a cure for sickle-cell disease, marking the first approval...

2024-01-03 13:51:32 ET More on Agios Pharmaceuticals, bluebird bio, etc. Crispr Therapeutics Is Overvalued (Rating Downgrade) bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market...

ZUG, Switzerland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 42nd Annual J...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...